1.
Cryopreserved hematopoietic stem/progenitor cells stability program-development, current status and recommendations: A brief report from the AABB-ISCT joint working group cellular therapy product stability project team
Reich-Slotky, R., Vasovic, L. V., Land, K. J., Halpenny, M., Woeltz, J., Mathew, A. J., Fournier, D., Alder, B., Stasko, K., Mahmud, N.
Cytotherapy. 2022
Abstract
BACKGROUND The AABB-ISCT Joint Working Group Stability Project Team (SPT) was assigned to roadmap a path toward standardization of cryopreserved hematopoietic stem/progenitor cell (HSPC) stability programs. HSPC stability encompasses a broad scope of conditions including non-frozen ("fresh") and cryopreserved cell products, and varying methods for storage, thaw, and administration. This report assessed current practices and focused solely on cryopreserved HSPC cell therapy products to establish preliminary recommendations for a stability program roadmap. METHODS A survey was prepared by the SPT and distributed to ISCT and AABB members. Survey results were summarized and recommendations were outlined based on the responses from the survey. This report highlights current practices for cryopreserved HSPC stability programs, including additional considerations and recommendations. RESULTS AND DISCUSSION Eighty-two (82) centers worldwide participated in the survey. Survey results indicate variability across programs. HSPC stability depends on multiple factors within the processing facility (e.g., cryopreservation techniques, reagents used, and storage temperature) and independent variables (e.g., donor-related factors and starting material variability). While retention of hematopoietic engraftment potential is the primary goal for cryopreserved HSPC stability, engraftment results should not be used as the sole metric for stability programs. Based on the survey results, the SPT provides recommendations for consideration. CONCLUSIONS The SPT recommendations for best practices are not intended to replace existing standards. The survey results emphasize the need for the community to optimize best practices and consider initiating collaborative projects to improve the standardization of cryopreserved HSPC stability programs for cell therapy products.
2.
[Method and impact of allografts cryopreservation during the Covid-19 pandemic: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]
Forcade, E., Bacquet, S., Ballot, C., Capin, L., Garnier, F., Giraud, C., Guérout-Vérité, M. A., Letellier, C., Magnani, A., Mamez, A. C., et al
Bulletin du cancer. 2022
Abstract
The COVID-19 pandemic disorganized the allogeneic stem cell transplantation activities all over the world, with the necessity to cryopreserve allografts to secure the procedure for both the recipient and the donor. Cryopreservation, usually anecdotal, has been used by all the French speaking centers; data collected from 24 centers were assessed in order to determine the impact of cryopreservation on the quality of allografts. Our analysis clearly demonstrates that increasing transit time (more than 48hours) is deleterious for CD34(+) recovery, legitimates the slight increase of the requested CD34(+) cell dose with respect to the average recovery rate as well as the importance of the quality control on the infused product.
3.
[Preservation/congelation of hematopoietic stem cell grafts in a pediatric context: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. [Review] [French]
De Vos, J., de Berranger, E., Jubert, C., Pochon, C., Letellier, C., Mialou, V., Sirvent, A., Yakoub-Agha, I., Dalle, J. H.
Bulletin du Cancer. 2017;104(12S):S136-S141
Abstract
The Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) organized the 7th allogeneic hematopoietic stem cell transplantation clinical practices harmonization workshop series in September 2016 in Lille, France. The objective of our workshop is to provide a discussion on the conservation and congelation of hematopoietic stem cells in a pediatric setting as well as our recommendations for this technique.Copyright © 2017 Societe Francaise du Cancer. Published by Elsevier Masson SAS. All rights reserved.